Early CAR T Therapy Enhances Outcomes for High-Risk Tumors

Early introduction of a treatment called AXI-CEL could improve the performance of high-risk tumors, according to a phase ii trial conducted by U.S. scientists and published in The Journal Nature Medicine. It activated a complete response in 78% of 37 high-risk large B-cell lymphoma (LBCL) patients. Axi-cel is a CAR-T immunotherapy that specifically targets the surface protein CD19 of cancerous B cells. The results suggest that this type of CAR T cell therapy is safe, early or more clinically beneficial than usual.